Literature DB >> 16621901

Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma.

Gavin C Mackie1, Barry L Shulkin, Raul C Ribeiro, Francis P Worden, Paul G Gauger, Rajen J Mody, Len P Connolly, Ghada Kunter, Carlos Rodriguez-Galindo, Jerold W Wallis, Craig A Hurwitz, David E Schteingart.   

Abstract

CONTEXT: Adrenocortical carcinomas are uncommon, and their evaluation by [(18)F]fluorodeoxyglucose positron emission tomography (FDG PET) has not been well evaluated.
OBJECTIVE: The purpose of this study was to examine the potential utility of FDG PET in the detection of recurrent or metastatic adrenocortical carcinoma.
DESIGN: In patients with known adrenocortical carcinoma who underwent FDG-PET imaging for suspected recurrence or metastasis, FDG activity was compared with other imaging findings, clinical features, and the presence or absence of disease as confirmed by resection, biopsy, or clinical follow-up.
SETTING: The study took place at four tertiary referral centers. PATIENTS OR OTHER PARTICIPANTS: Twelve patients (10 females and two males, 5-71 yr of age) were evaluated. MAIN OUTCOME MEASURES: The main outcome measures were FDG activity, other imaging findings, and clinical features.
RESULTS: Abnormal FDG uptake correctly indicated tumor recurrence in 10 patients. One patient with no abnormal FDG activity had a morphological abnormality subsequently proven to be a postoperative scar. Two patients, one with very small pulmonary lesions and one with a hepatic metastasis, had false-negative findings.
CONCLUSIONS: Most adrenocortical carcinomas accumulate and retain FDG and thus can be visualized by PET. However, false-negative findings are possible, especially with very small lesions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16621901     DOI: 10.1210/jc.2005-2612

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  19 in total

Review 1.  FDG PET in the management of patients with adrenal masses and adrenocortical carcinoma.

Authors:  Désirée Deandreis; Sophie Leboulleux; Caroline Caramella; Martin Schlumberger; Eric Baudin
Journal:  Horm Cancer       Date:  2011-12       Impact factor: 3.869

Review 2.  Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma.

Authors:  Irina Veytsman; Lynnette Nieman; Tito Fojo
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

Review 3.  Surgical management of adrenocortical tumours.

Authors:  Barbra S Miller; Gerard M Doherty
Journal:  Nat Rev Endocrinol       Date:  2014-03-18       Impact factor: 43.330

Review 4.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

5.  Adrenocortical Carcinoma: False Positive in an I-123 Metaiodobenzylguanedine Scan.

Authors:  Cristina Rodríguez Rey; Aída Ortega Candil; Eliseo Vañó Galván; María Nieves Cabrera Martín; José Luis Carreras Delgado
Journal:  Nucl Med Mol Imaging       Date:  2015-06-03

6.  Preoperative 18F-FDG uptake is strongly correlated with malignancy, Weiss score, and molecular markers of aggressiveness in adrenal cortical tumors.

Authors:  Lucile Gust; David Taieb; Arnault Beliard; Anne Barlier; Isabelle Morange; Catherine de Micco; Jean-François Henry; Frederic Sebag
Journal:  World J Surg       Date:  2012-06       Impact factor: 3.352

7.  Impact of ¹⁸F-FDG PET/CT on the management of adrenocortical carcinoma: analysis of 106 patients.

Authors:  Satoshi Takeuchi; Aparna Balachandran; Mouhammed Amir Habra; Alexandria T Phan; Roland L Bassett; Homer A Macapinlac; Hubert H Chuang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07-03       Impact factor: 9.236

8.  Assessment of tumor heterogeneity in treatment-naïve adrenocortical cancer patients using (18)F-FDG positron emission tomography.

Authors:  Rudolf A Werner; Matthias Kroiss; Masatoyo Nakajo; Dirk O Mügge; Stefanie Hahner; Martin Fassnacht; Andreas Schirbel; Christina Bluemel; Takahiro Higuchi; Laszló Papp; Norbert Zsótér; Andreas K Buck; Ralph A Bundschuh; Constantin Lapa
Journal:  Endocrine       Date:  2016-05-02       Impact factor: 3.633

9.  (18)F-FDG uptake at initial staging of the adrenocortical cancers: a diagnostic tool but not of prognostic value.

Authors:  L Tessonnier; C Ansquer; C Bournaud; F Sebag; E Mirallié; J C Lifante; F F Palazzo; I Morange; D Drui; C de la Foucardère; J Mancini; D Taïeb
Journal:  World J Surg       Date:  2013-01       Impact factor: 3.352

10.  Hemoglobin level significantly impacts the tumor cell survival fraction in humans after internal radiotherapy.

Authors:  Stephan Walrand; Renaud Lhommel; Pierre Goffette; Marc Van den Eynde; Stanislas Pauwels; François Jamar
Journal:  EJNMMI Res       Date:  2012-05-19       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.